Status:
RECRUITING
Role of Mesenchymal Stromal Cell Derived Extracellular Vesicles of Primary Myelofibrosis Patients on CD34+ Cells
Lead Sponsor:
Fondazione IRCCS Policlinico San Matteo di Pavia
Conditions:
Primary Myelofibrosis
Eligibility:
All Genders
18+ years
Brief Summary
The aim of this study is to demonstrate that, in patients with myelofibrosis (PMF), a chronic neoplastic disease of the bone marrow, some of the cells that form the bone marrow microenvironment (mesen...
Detailed Description
Primary myelofibrosis (PMF) is a chronic myeloproliferative neoplasm characterized by the clonal proliferation of CD34+ progenitor cells. A constitutive activation of the JAK-STAT pathway, due to an a...
Eligibility Criteria
Inclusion
- Patients with PMF
- JAK2 V617F+ (either homozygous or heterozygous)
- Out of therapy
- At least 18 years old
Exclusion
- PMF combined to other pathologies
- Previous splenectomy
- Previous bone marrow transplant
Key Trial Info
Start Date :
January 11 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 1 2025
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT06896344
Start Date
January 11 2024
End Date
August 1 2025
Last Update
April 2 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Fondazione IRCCS Policlinico San Matteo di Pavia
Pavia, Pavia, Italy, 27100